Sitagliptin
- Generic Name
- Sitagliptin
- Brand Names
- Janumet, Januvia, Ristaben, Steglujan, Tesavel, Velmetia, Xelevia, Sitagliptin SUN, Sitagliptin Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H15F6N5O
- CAS Number
- 486460-32-6
- Unique Ingredient Identifier
- QFP0P1DV7Z
- Background
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar. Sitagliptin was granted FDA approval on October 16, 2006.
- Indication
Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not used to treat type 1 diabetes or patients with a history of pancreatitis.
It is also used in combination with metformin or ertugliflozin.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2008-08-07
- Last Posted Date
- 2015-04-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 83
- Registration Number
- NCT00729326
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-07-16
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 121
- Registration Number
- NCT00716092
- Locations
- 🇩🇪
1218.37.49003 Boehringer Ingelheim Investigational Site, Berlin, Germany
🇩🇪1218.37.49002 Boehringer Ingelheim Investigational Site, Mainz, Germany
🇩🇪1218.37.49001 Boehringer Ingelheim Investigational Site, Neuss, Germany
The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 665
- Registration Number
- NCT00700817
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Swansea, United Kingdom
A Study to Test the Safety and Efficacy of Sitagliptin Compared to Glimepiride in Patients With Type 2 Diabetes on a Stable Dose of Metformin (0431-803)(COMPLETED)
- Conditions
- Type 2 Diabetes Mellitus, Non Insulin DependentDiabetes Mellitus, Non-Insulin-Dependent
- Interventions
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1035
- Registration Number
- NCT00701090
Effect of Dipeptidyl Peptidase-IV Inhibitor and Sulfonylurea on Glucose Variability and Oxidative Stress
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2009-10-29
- Lead Sponsor
- The Catholic University of Korea
- Target Recruit Count
- 36
- Registration Number
- NCT00699322
- Locations
- 🇰🇷
Kangnam St. Mary's hospital, Seoul, Korea, Republic of
The Effect of Sitagliptin on Hypertension, Arterial Stiffness, Oxidative Stress and Inflammation
- Conditions
- Diabetes MellitusArterial Stiffness
- Interventions
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2008-06-13
- Lead Sponsor
- Assaf-Harofeh Medical Center
- Target Recruit Count
- 60
- Registration Number
- NCT00696982
- Locations
- 🇮🇱
Department of Internal Medicine A , Research & Development unit Assaf Harofeh Medical Center, Zerifin, affiliated to Sackler School of Medicine, Tel Aviv, Israel, Zrifin, Israel
Sitagliptin in Combination With Metformin and Sulfonylurea
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2014-11-26
- Lead Sponsor
- Charles Drew University of Medicine and Science
- Target Recruit Count
- 108
- Registration Number
- NCT00686634
- Locations
- 🇺🇸
Charles Drew University of Medicine and Science, Los Angeles, California, United States
Quantification of the Dipeptidyl Peptidase (DPP)-4 Inhibition-mediated Enhancement of the Activity of the Entero-insular Axis
- First Posted Date
- 2008-05-23
- Last Posted Date
- 2015-12-18
- Lead Sponsor
- Michael A. Nauck
- Target Recruit Count
- 20
- Registration Number
- NCT00683735
- Locations
- 🇩🇪
Diabeteszentrum Bad Lauterberg, Bad Lauterberg, Germany
Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2008-05-13
- Last Posted Date
- 2015-04-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 820
- Registration Number
- NCT00676338
- Locations
- 🇬🇧
Research Site, Swansea, United Kingdom
🇮🇱Research SIte, Tel-Hashomer, Israel
Effects of Glutamine on GLP-1 and Insulin Secretion in Man
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2019-05-13
- Lead Sponsor
- Garvan Institute of Medical Research
- Target Recruit Count
- 22
- Registration Number
- NCT00673894
- Locations
- 🇦🇺
Clinical Research Facility, Sydney, New South Wales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.